Activity Provided By:

ACHL

Therapeutic Advancements for the Treatment of High-Risk MDS: Future Opportunities to Improve Patient Survival and Quality of Life

Overview / Abstract:	Stay up to date on the evolving risk classification for myelodysplastic syndromes (MDS) and current treatment guidelines for patients with high-risk disease in this self-directed education with leading oncology experts. Expert commentary from Courtney DiNardo, MD from MD Anderson Cancer Center and Dr. Dan Pollyea from the University of Colorado School of Medicine provides insights on emerging therapies that could soon improve management of high-risk MDS. Be ready to incorporate these emerging therapies into your treatment plans to best meet the needs of your patients and get the answers you need about MDS classification and risk assessment.
Expiration	Oct 27, 2024
Discipline(s)	Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME
Format	Online, Webinar / Webcast / Video
Credits / Hours	1.0
Accreditation	ACCME, AAPA, ANCC
Presenters / Authors / Faculty	Courtney DiNardo, MD, MSCE Associate Professor Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, TX Daniel Pollyea, MD, MS Professor of Medicine Clinical Director of Leukemia Services Associate Chief of Clinical Affairs Robert H. Allen MD Chair in Hematology Research Division of Hematology University of Colorado School of Medicine Aurora, CO
Sponsors / Supporters / Grant Providers	Provided by The University of Texas MD Anderson Cancer Center and the Academy for Continued Healthcare Learning (ACHL). The organizing committee wishes to express appreciation to the following company for their commitment to continuing medical education by providing an educational grant in support of this educational activity: Gilead Sciences, Inc.
Keywords / Search Terms	ACHL Pollyea, DiNardo, hematology, pathology, oncology, transfusion, MDS, myelodysplastic syndromes, high-risk MDS, HR-MDS, CD47, immune surveillance, mechanism of action, MOA, cytopenia, hemoglobin, dysplasia, cytogenetic testing, cytogenetics, karyotype, multidisciplinary, biopsy, neutropenia, myeloid neoplasm, hematopoiesis, bone marrow, hypercellularity, mutational testing, NGS, next generation sequencing, hypomethylating agent, HMA, azacitidine, AZA, decitabine, DAC, cedazuradine, macrocytic anemia, anemia, Revised International Prognostic Scoring System, IPSS-R, IPSS-molecular, IPSS-M, TP53, magrolimab, sabatolimab, venetoclax Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map